Clinical Trial

AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA

Study acronym: DURVASCC
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II, single-arm, multicenter study to evaluate the activity and safety of durvalumab in combination with carboplatin or cisplatin plus etoposide in patients with treated ES-EPSCC.
Trial Details
NCT Number NCT06464068
Lead Sponsor Gruppo Oncologico Italiano di Ricerca Clinica
Conditions Extrapulmonary Small Cell Carcinoma
Enrollment 66 participants
Start Date 2024-01-16
Primary Completion 2028-01-01 (estimated)
Study Completion 2028-01-01 (estimated)
Updated on ClinicalTrials.gov 2024-06-18